Finance

Beta
Lists
BBNX:NASDAQ
Beta Bionics Inc
$16.82
+5.72%
(+0.91) 1D
$16.82
-0.00% (-0.00030)
After hours
Closed: Jun 26, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BBNX...
Open
$15.82
High
$17.11
Low
$15.64
Mkt. cap
749.53M
Avg. vol.
948.54K
Volume
2.04M
52-wk high
$32.71
52-wk low
$8.80
EPS
-$1.51
Shares outstanding
44.56M
No. of employees
422
Open
$15.82
High
$17.11
Low
$15.64
Mkt. cap
749.53M
Avg. vol.
948.54K
Volume
2.04M
52-wk high
$32.71
52-wk low
$8.80
EPS
-$1.51
Shares outstanding
44.56M
No. of employees
422
News stories
From sources across the web
About Beta Bionics Inc
CEO-
Employees422
Founded2015
HeadquartersIrvine, California, United States
SectorMedical device
Websitebetabionics.com
Analyst ratings
Based on 7 analysts giving stock ratings to BBNX in the past 3 months
Buy
Buy
5
Hold
2
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for BBNX in the last 3 months.
Highest
Current $16.82
$20.00 (+18.91%)
Average
$17.67 (+5.05%)
Lowest
$13.00 (-22.71%)
Analyst
Recommendation
Action
Price target
Projected
Date
Frank Takkinen
Lake Street
Buy
Reiterated
$20.00
+18.9%
06/24/2026
Matthew O'Brien
Piper Sandler
Buy
Reiterated
$20.00
+18.9%
06/22/2026
David Roman
Goldman Sachs
Buy
Maintained
$17.00
+1.1%
05/27/2026
Richard Newitter
Truist Financial
Buy
Maintained
-
-
05/22/2026
Travis Steed
Bank of America Securities
Hold
Reiterated
$13.00
-22.7%
05/21/2026
Jonathan Block
Stifel Nicolaus
Buy
Maintained
$20.00
+18.9%
04/22/2026
Mathew Blackman
TD Cowen
Hold
Maintained
$16.00
-4.9%
04/21/2026
Jeff Johnson
Robert W. Baird
Hold
Maintained
$14.00
-16.8%
02/18/2026
Danielle Antalffy
UBS
Buy
Reiterated
$24.00
+42.7%
02/18/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
23.24M
27.25M
32.12M
27.63M
Cost of goods sold
10.74M
12.13M
13.18M
11.19M
Cost of revenue
10.74M
12.13M
13.18M
11.19M
Research and development expenses
8.87M
8.20M
10.13M
10.36M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
23.50M
23.97M
24.94M
30.35M
Operating expense
32.38M
32.16M
35.07M
40.71M
Total operating expenses
43.11M
44.30M
48.24M
51.90M
Operating income
-19.87M
-17.04M
-16.12M
-24.27M
Other non operating income
-2.00K
1.00K
-
-
EBT including unusual items
-16.87M
-14.21M
-13.47M
-21.90M
EBT excluding unusual items
-16.87M
-14.21M
-13.47M
-21.90M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-16.87M
-14.21M
-13.47M
-21.90M
Net profit margin
-72.59%
-52.14%
-41.92%
-79.25%
Earnings per share
-0.27
-0.33
-0.19
-0.36
Interest and investment income
3.00M
2.83M
2.66M
2.38M
Interest expense
-
-
-
-
Net interest expenses
3.00M
2.83M
2.66M
2.38M
Depreciation and amortization charges
-
-
-
-
EBITDA
-19.52M
-16.66M
-15.59M
-23.69M
Gain or loss from assets sale
-
-
31.00K
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
Give me an overview of BBNX
Explore what’s possible
Create portfolio
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer